305 related articles for article (PubMed ID: 29700965)
1. BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes.
Takeda K; Taguri M; Morita S
Pharm Stat; 2018 Jul; 17(4):383-395. PubMed ID: 29700965
[TBL] [Abstract][Full Text] [Related]
2. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
Takeda K; Morita S; Taguri M
Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
[TBL] [Abstract][Full Text] [Related]
3. gBOIN-ET: The generalized Bayesian optimal interval design for optimal dose-finding accounting for ordinal graded efficacy and toxicity in early clinical trials.
Takeda K; Morita S; Taguri M
Biom J; 2022 Oct; 64(7):1178-1191. PubMed ID: 35561046
[TBL] [Abstract][Full Text] [Related]
4. A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies.
Zhou Y; Lee JJ; Yuan Y
Stat Med; 2019 Dec; 38(28):5299-5316. PubMed ID: 31621952
[TBL] [Abstract][Full Text] [Related]
5. Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.
Yuan Y; Hess KR; Hilsenbeck SG; Gilbert MR
Clin Cancer Res; 2016 Sep; 22(17):4291-301. PubMed ID: 27407096
[TBL] [Abstract][Full Text] [Related]
6. TITE-gBOIN-ET: Time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes.
Takeda K; Yamaguchi Y; Taguri M; Morita S
Biom J; 2023 Oct; 65(7):e2200265. PubMed ID: 37309248
[TBL] [Abstract][Full Text] [Related]
7. A Bayesian optimal interval design for dose optimization with a randomization scheme based on pharmacokinetics outcomes in oncology.
Takeda K; Zhu J; Li R; Yamaguchi Y
Pharm Stat; 2023; 22(6):1104-1115. PubMed ID: 37545018
[TBL] [Abstract][Full Text] [Related]
8. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
[TBL] [Abstract][Full Text] [Related]
9. Bayesian optimal interval design with multiple toxicity constraints.
Lin R
Biometrics; 2018 Dec; 74(4):1320-1330. PubMed ID: 29870069
[TBL] [Abstract][Full Text] [Related]
10. Bayesian dose-finding phase I trial design incorporating historical data from a preceding trial.
Takeda K; Morita S
Pharm Stat; 2018 Jul; 17(4):372-382. PubMed ID: 29372582
[TBL] [Abstract][Full Text] [Related]
11. Bayesian dose-finding phase I trial design incorporating pharmacokinetic assessment in the field of oncology.
Takeda K; Komatsu K; Morita S
Pharm Stat; 2018 Nov; 17(6):725-733. PubMed ID: 30066356
[TBL] [Abstract][Full Text] [Related]
12. A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.
Zang Y; Lee JJ
Stat Med; 2017 Jan; 36(1):27-42. PubMed ID: 27538818
[TBL] [Abstract][Full Text] [Related]
13. Incorporating historical information to improve dose optimization design with toxicity and efficacy endpoints: iBOIN-ET.
Zhao Y; Liu R; Takeda K
Pharm Stat; 2023; 22(3):440-460. PubMed ID: 36514849
[TBL] [Abstract][Full Text] [Related]
14. Comparison Between Simultaneous and Sequential Utilization of Safety and Efficacy for Optimal Dose Determination in Bayesian Model-Assisted Designs.
Li R; Takeda K; Rong A
Ther Innov Regul Sci; 2023 Jul; 57(4):728-736. PubMed ID: 37087525
[TBL] [Abstract][Full Text] [Related]
15. Improving early phase oncology clinical trial design: The case for finding the optimal biological dose.
Phillips A; Mondal S
Pharm Stat; 2023; 22(4):739-747. PubMed ID: 36669771
[TBL] [Abstract][Full Text] [Related]
16. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
Lin R; Yin G
Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
[TBL] [Abstract][Full Text] [Related]
17. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
Du Y; Yin J; Sargent DJ; Mandrekar SJ
J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
[TBL] [Abstract][Full Text] [Related]
18. Surv-CRM-12: A Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression.
Andrillon A; Chevret S; Lee SM; Biard L
Stat Med; 2022 Dec; 41(29):5753-5766. PubMed ID: 36259523
[TBL] [Abstract][Full Text] [Related]
19. Adaptive design for identifying maximum tolerated dose early to accelerate dose-finding trial.
Kojima M
BMC Med Res Methodol; 2022 Apr; 22(1):97. PubMed ID: 35382745
[TBL] [Abstract][Full Text] [Related]
20. A Bayesian design for finding optimal biological dose with mixed types of responses of toxicity and efficacy.
Zhang D; Xu J
Contemp Clin Trials; 2023 Apr; 127():107113. PubMed ID: 36758934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]